Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today announced ...

“The completion of enrollment in our Phase 2a trial marks an important step in advancing a non-steroidal, locally delivered treatment for oral lichen planus, an underserved condition with no FDA ...

which is aimed at treating oral lichen planus (OLP). The dose-ranging trial has ultimately enrolled subjects across the tacrolimus’ 0.25mg, 0.50mg and 1.0mg dose cohorts at seven trial sites in ...

“The completion of enrollment in our Phase 2a trial marks an important step in advancing a non-steroidal, locally delivered treatment for oral lichen planus, an underserved condition with no ...

PITTSBURGH, April 08, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology ...

which is aimed at treating oral lichen planus (OLP). The dose-ranging trial has ultimately enrolled subjects across the tacrolimus’ 0.25mg, 0.50mg and 1.0mg dose cohorts at seven trial sites in the US ...

Elixir. The most widely used medication is dexamethasone elixir at 0.1 mg/mL, swirling approximately 5 mL for 3 minutes four times a day and then spitting out. [9] Azathioprine may be used in ...

China: A recent study has found that in patients with Hashimoto's thyroiditis (HT), the presence of thyroid nodules, a higher FT3/FT4 ratio, and positive thyroglobulin antibodies were associated with ...